Zimmer Biomet Lowers FY24 Outlook: Adj EPS from $8.00-$8.15 to $7.95-$8.05 vs $7.95 Est, Revenue Growth Of 3.5%-4% (4%-5% Prior)
Portfolio Pulse from Benzinga Newsdesk
Zimmer Biomet has revised its financial guidance for FY24, lowering its adjusted EPS forecast to $7.95-$8.05 from $8.00-$8.15 and reducing its revenue growth projection to 3.5%-4% from 4%-5%.
October 30, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Zimmer Biomet has lowered its FY24 financial guidance, reducing its adjusted EPS forecast to $7.95-$8.05 and its revenue growth projection to 3.5%-4%.
The reduction in both EPS and revenue growth forecasts suggests potential challenges in achieving previous financial targets, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100